Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property

Alphagen signs definitive agreement for Quantum Vision

AIC · Price

Executive Summary

  • Alphagen Intelligence Corp. has entered into a definitive share exchange agreement to acquire 100% of Quantum Vision Holdings Inc., constituting a fundamental change under CSE policies.
  • The transaction will be settled via the issuance of 24,500,001 Alphagen common shares (valued at $0.40 per share) in a 1:1 exchange ratio for all outstanding Quantum Vision shares.
  • Quantum Vision, a development-stage postquantum security infrastructure company, will become a wholly-owned subsidiary, with Kyle Klemmer appointed as CEO and Matthew Morgan joining the board of directors.

Key Details

  • Transaction Structure: Definitive share exchange agreement for the acquisition of all issued and outstanding shares of Quantum Vision Holdings Inc.
  • Consideration & Valuation: Alphagen will issue 24,500,001 common shares to Quantum Vision shareholders, representing a 1:1 exchange ratio at a deemed value of $0.40 per Alphagen share.
  • Completion Timeline: Anticipated to close no later than July 31, 2026, subject to satisfaction or waiver of conditions precedent.
  • Regulatory & Exchange Status: Trading in Alphagen common shares is halted pending CSE approval for the transaction and listing of applicable securities; trading will resume upon CSE acceptance of required documentation.
  • Shareholder Approval: Required due to fundamental change status; approval needed via written consent (50.01%+) or at a shareholders' meeting (majority vote).
  • Management & Board Changes: Kyle Klemmer (current CEO of Quantum Vision) will become CEO of the resulting issuer; Matthew Morgan will join the board of directors. All current Alphagen directors will remain.
  • Finders' Fees: None payable in connection with the transaction.
  • Target Company Profile: Quantum Vision is a development-stage security infrastructure company developing postquantum cryptographic solutions aligned with NIST standards (FIPS 203, 204, 205) for healthcare, government, defense, aerospace, and critical infrastructure.
  • Target Financials & Operations: No revenues generated since inception; nominal assets consisting primarily of intangible assets and cash with minimal liabilities; currently advancing multiple products toward prototype phase and commercialization.
  • Additional Disclosures: Further financial and operational details regarding Quantum Vision and the resulting issuer will be provided in the upcoming CSE listing statement.
Read the original news release →

More from Alphagen Intelligence Corp